- Home
- FINW vs ACIU Comparison
FINW vs ACIU Comparison
Compare FINW & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- ACIU
- Stock Information
- Founded
- FINW 1999
- ACIU 2003
- Country
- FINW United States
- ACIU Switzerland
- Employees
- FINW N/A
- ACIU N/A
- Industry
- FINW Commercial Banks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- ACIU Health Care
- Exchange
- FINW Nasdaq
- ACIU Nasdaq
- Market Cap
- FINW 207.1M
- ACIU 213.3M
- IPO Year
- FINW 2021
- ACIU 2016
- Fundamental
- Price
- FINW $18.51
- ACIU $2.13
- Analyst Decision
- FINW Buy
- ACIU Strong Buy
- Analyst Count
- FINW 4
- ACIU 1
- Target Price
- FINW $20.75
- ACIU $12.00
- AVG Volume (30 Days)
- FINW 19.2K
- ACIU 160.7K
- Earning Date
- FINW 07-24-2025
- ACIU 08-05-2025
- Dividend Yield
- FINW N/A
- ACIU N/A
- EPS Growth
- FINW N/A
- ACIU N/A
- EPS
- FINW 0.96
- ACIU N/A
- Revenue
- FINW $74,999,000.00
- ACIU $36,362,036.00
- Revenue This Year
- FINW $50.70
- ACIU N/A
- Revenue Next Year
- FINW $22.82
- ACIU $533.21
- P/E Ratio
- FINW $19.26
- ACIU N/A
- Revenue Growth
- FINW 10.21
- ACIU 86.71
- 52 Week Low
- FINW $11.92
- ACIU $1.43
- 52 Week High
- FINW $20.94
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- FINW 63.63
- ACIU 48.82
- Support Level
- FINW $17.66
- ACIU $2.05
- Resistance Level
- FINW $19.64
- ACIU $2.25
- Average True Range (ATR)
- FINW 0.63
- ACIU 0.17
- MACD
- FINW 0.02
- ACIU -0.02
- Stochastic Oscillator
- FINW 57.91
- ACIU 19.57
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.